Gilead Sciences (GILD) News $GILD
7 Undeniable Reasons to Invest in Health Care
Keith Speights, The Motley Fool - Motley Fool - 2 hrs 47 mins ago
You need to be in health care. There are no ifs, ands, or buts about it. I'm not talking about working in the health-care industry (although that's not a bad idea, either). At least part of your investment portfolio needs to be in health care...
Biotech Tweets of the Week: Gilead Sciences and Orexigen
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 7:49PM CDT
Not on twitter? (That should include some of you.) Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.) Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to...
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 21, 7:05PM CDT
Cramer will be watching earnings from a slew of companies and awaiting China's manufacturing PMI number.
Good News for Johnson & Johnson - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:30PM CDT
Johnson & Johnson halted an early phase III study on a three-month formulation of Invega Sustenna.
Biotechs, Medicals Get Hurt Amid Price-Inquiry News
at Investor's Business Daily - Fri Mar 21, 5:26PM CDT
Two normally healthy biotech stocks suffered critical declines Friday, while most other medical names on the IBD 50 remained in fairly stable condition. Still, the biotech illness spread to other drug stocks. As a result, six of the seven biggest...
Most active Nasdaq-traded stocks
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Biotechs, Software, Generics Pace U.S. Stocks Lower
at Investor's Business Daily - Fri Mar 21, 4:04PM CDT
Stocks lost initial gains as a summary sell-off of biotech and ethical drug names punched the Nasdaq composite sharply lower. All but two of the top 10 stocks within the IBD 50 also fell. The Nasdaq composite fell nearly 1%. That shaved the index's...
Cambrex Keeps Its Pipeline Of New Products Flowing
at Investor's Business Daily - Fri Mar 21, 3:50PM CDT
For most pharmaceutical companies, keeping a pipeline of new drugs filled is critical to success. Steven Klosk, president and CEO of East Rutherford, N.J.-based Cambrex (CBM), specializes in developing a pipeline of new medications as an outsourcer...
U.S. Stocks Lose Gains, Biotechs Get Hammered
at Investor's Business Daily - Fri Mar 21, 3:26PM CDT
Stocks lost initial gains as a summary sell-off of biotech and ethical drug names punched the Nasdaq composite sharply lower Friday. The Nasdaq composite fell nearly 1%. That shaved the index's weekly advance to less than 0.8%. The S&P 500's 0.6%...
Favorable Data for Myriad Genetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 2:30PM CDT
Shares of Myriad Genetics gained 1.78% at yesterday's close.
Why Biogen Idec (BIIB) Is Down Today
at The Street - Fri Mar 21, 1:30PM CDT
Biogen Idec (BIIB) dropped on Friday as the biotech sector sagged amid controversy tied to Gilead Sciences' (GILD) hepatitis C drug Sovaldi, which has been priced at $1,000 a day. The drop comes despite news that Health Canada has approved Biogen...
Biotech Stocks Weak on Fear That Gilead Drug Pricing Woes Will Spread
at The Street - Fri Mar 21, 1:02PM CDT
Investors are spooked that heightened scrutiny over Gilead's Hep C drug will cause a backlash across the entire biotech sector.
Midday Glance: Biotechnology companies
AP - Fri Mar 21, 12:24PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Gilead Pricing Probed By House; Biotech Stocks Drop
at Investor's Business Daily - Fri Mar 21, 11:29AM CDT
Biotech stocks were selling off hard Friday, and consensus on Wall Street seemed to pin the blame on a letter sent by several House Democrats to Gilead Sciences (GILD) asking for a briefing on the price of its hepatitis C blockbuster Sovaldi. The...
Nasdaq Back Above Water; Green Plains Jumps
at Investor's Business Daily - Fri Mar 21, 10:54AM CDT
Stocks were higher in unison once again near Friday's halftime after trading mixed earlier. The Dow Jones industrial average rose 0.7%, while the S&P 500 climbed 0.6%. After falling as much as 0.6% earlier, the Nasdaq has turned fractionally higher....
Trial Protocol Submission Lifts Heat Biologics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 10:30AM CDT
Shares of Heat Biologics gained more than 8% to close the trading session on March 20 at $7.42 .
Early Glance: Biotechnology companies
AP - Fri Mar 21, 9:46AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Dow, S&P 500 Up, Nasdaq Slips; Drugmakers Falling Hard
at Investor's Business Daily - Fri Mar 21, 9:31AM CDT
Stocks got off to a positive start Friday, but slipped into mixed trade as several drugmakers fell abruptly and pulled the Nasdaq into negative territory. The Dow Jones industrial average was ahead 0.4%, the S&P 500 up 0.3%. The Nasdaq fell 0.3%,...
7 Undeniable Reasons to Invest in Health Care
Keith Speights, The Motley Fool - Motley Fool - 2 hrs 47 mins ago
You need to be in health care. There are no ifs, ands, or buts about it. I'm not talking about working in the health-care industry (although that's not a bad idea, either). At least part of your investment portfolio needs to be in health care...
Biotech Tweets of the Week: Gilead Sciences and Orexigen
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 7:49PM CDT
Not on twitter? (That should include some of you.) Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.) Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to...
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 21, 7:05PM CDT
Cramer will be watching earnings from a slew of companies and awaiting China's manufacturing PMI number.
Good News for Johnson & Johnson - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:30PM CDT
Johnson & Johnson halted an early phase III study on a three-month formulation of Invega Sustenna.
Biotechs, Medicals Get Hurt Amid Price-Inquiry News
at Investor's Business Daily - Fri Mar 21, 5:26PM CDT
Two normally healthy biotech stocks suffered critical declines Friday, while most other medical names on the IBD 50 remained in fairly stable condition. Still, the biotech illness spread to other drug stocks. As a result, six of the seven biggest...
Most active Nasdaq-traded stocks
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Biotechs, Software, Generics Pace U.S. Stocks Lower
at Investor's Business Daily - Fri Mar 21, 4:04PM CDT
Stocks lost initial gains as a summary sell-off of biotech and ethical drug names punched the Nasdaq composite sharply lower. All but two of the top 10 stocks within the IBD 50 also fell. The Nasdaq composite fell nearly 1%. That shaved the index's...
Cambrex Keeps Its Pipeline Of New Products Flowing
at Investor's Business Daily - Fri Mar 21, 3:50PM CDT
For most pharmaceutical companies, keeping a pipeline of new drugs filled is critical to success. Steven Klosk, president and CEO of East Rutherford, N.J.-based Cambrex (CBM), specializes in developing a pipeline of new medications as an outsourcer...
U.S. Stocks Lose Gains, Biotechs Get Hammered
at Investor's Business Daily - Fri Mar 21, 3:26PM CDT
Stocks lost initial gains as a summary sell-off of biotech and ethical drug names punched the Nasdaq composite sharply lower Friday. The Nasdaq composite fell nearly 1%. That shaved the index's weekly advance to less than 0.8%. The S&P 500's 0.6%...
Favorable Data for Myriad Genetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 2:30PM CDT
Shares of Myriad Genetics gained 1.78% at yesterday's close.
Why Biogen Idec (BIIB) Is Down Today
at The Street - Fri Mar 21, 1:30PM CDT
Biogen Idec (BIIB) dropped on Friday as the biotech sector sagged amid controversy tied to Gilead Sciences' (GILD) hepatitis C drug Sovaldi, which has been priced at $1,000 a day. The drop comes despite news that Health Canada has approved Biogen...
Biotech Stocks Weak on Fear That Gilead Drug Pricing Woes Will Spread
at The Street - Fri Mar 21, 1:02PM CDT
Investors are spooked that heightened scrutiny over Gilead's Hep C drug will cause a backlash across the entire biotech sector.
Midday Glance: Biotechnology companies
AP - Fri Mar 21, 12:24PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Gilead Pricing Probed By House; Biotech Stocks Drop
at Investor's Business Daily - Fri Mar 21, 11:29AM CDT
Biotech stocks were selling off hard Friday, and consensus on Wall Street seemed to pin the blame on a letter sent by several House Democrats to Gilead Sciences (GILD) asking for a briefing on the price of its hepatitis C blockbuster Sovaldi. The...
Nasdaq Back Above Water; Green Plains Jumps
at Investor's Business Daily - Fri Mar 21, 10:54AM CDT
Stocks were higher in unison once again near Friday's halftime after trading mixed earlier. The Dow Jones industrial average rose 0.7%, while the S&P 500 climbed 0.6%. After falling as much as 0.6% earlier, the Nasdaq has turned fractionally higher....
Trial Protocol Submission Lifts Heat Biologics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 10:30AM CDT
Shares of Heat Biologics gained more than 8% to close the trading session on March 20 at $7.42 .
Early Glance: Biotechnology companies
AP - Fri Mar 21, 9:46AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Dow, S&P 500 Up, Nasdaq Slips; Drugmakers Falling Hard
at Investor's Business Daily - Fri Mar 21, 9:31AM CDT
Stocks got off to a positive start Friday, but slipped into mixed trade as several drugmakers fell abruptly and pulled the Nasdaq into negative territory. The Dow Jones industrial average was ahead 0.4%, the S&P 500 up 0.3%. The Nasdaq fell 0.3%,...
